Use this button to switch between dark and light mode.

Navigating Life Sciences M&A Deals Beyond COVID-19

March 15, 2022

Despite the various impacts of the COVID-19 pandemic, the life sciences industry has remained among the most active sectors for M&A activity. Check out this practice note, by Reb Wheeler of Mayer Brown LLP, focusing on issues common in life sciences M&A transactions and discussing some of the factors contributing to robust deal activity in the industry in recent years and what may be in store as industry participants continue to navigate a world transformed by COVID-19.       


Related Content

  • FDA Drug Regulatory Activity Tracker
    Stay current on the latest Food and Drug Administration regulatory guidance on medical drugs with this tracker from Practical Guidance’s Life Sciences practice area.


Practical Guidance Updates 
Featuring the latest updates from your Practical Guidance account.  

Experience results today with practical guidance, legal research, and data-driven insights—all in one place.

Experience Lexis+